56,134 XNAS Volume
XNAS 14 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| G. Kevin Lokay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Alleva Lawrence M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.07 per share. | 16 Aug 2024 | 67,015 | 265,029 (1%) | 0% | 0.1 | 4,825 | Common Stock |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 22,762 | 22,762 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 23,382 | 23,382 | - | - | Stock Option (Right to Buy) | |
| Kevin G. Lokay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 64,000 | 64,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Emmett Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 48,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bachleda | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 16 Mar 2023 | 11,000 | 11,000 (0%) | 0% | 2.2 | 24,717 | Common Stock |
| Christopher Degnan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.96 per share. | 13 Mar 2023 | 10,000 | 10,000 (0%) | 0% | 2.0 | 19,593 | Common Stock |
| J. Mel Sorensen | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.68 per share. | 10 Mar 2023 | 100,000 | 332,044 (1%) | 0% | 1.7 | 168,120 | Common Stock |
| Jennifer Evans Stacey | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 440,000 | 440,000 | - | - | Stock Option (Right to Buy) | |
| Eugene P. Kennedy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 185,000 | 185,000 | - | - | Stock Option (Right to Buy) | |
| Robert A. Beardsley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2022 | 10,000 | 75,651 | - | - | Stock Option | |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 21 Nov 2022 | 10,000 | 108,191 (0%) | 0% | 1.1 | 10,700 | Common Stock |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2022 | 10,000 | 85,651 | - | - | Stock Option | |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 12 Sep 2022 | 10,000 | 98,191 (0%) | 0% | 1.1 | 10,700 | Common Stock |
| Lawrence M. Alleva | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Jul 2022 | 4,000 | 2,325 (0%) | 0% | 0 | Common Stock | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 58,496 | 58,496 | - | - | Stock Option (Right to Buy) | |
| Kevin G. Lokay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Emmett Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Evans Stacey | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Jon T. Holmlund | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 264,400 | 264,400 | - | - | Stock Option (Right to Buy) | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Robert A. Beardsley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 20,000 | 95,651 | - | - | Stock Option | |
| Robert A. Beardsley | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 17 Dec 2021 | 20,000 | 88,191 (0%) | 0% | 1.1 | 21,400 | Common Stock |
| Linda West | Director | Purchase of securities on an exchange or from another person at price $ 2.74 per share. | 17 Dec 2021 | 20,000 | 60,000 (0%) | 0% | 2.7 | 54,804 | Common Stock |
| Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2021 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.43 per share. | 01 Sep 2021 | 47,756 | 47,756 (0%) | 0% | 2.4 | 116,047 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 47,756 | 61,142 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 01 Sep 2021 | 47,756 | 0 (0%) | 0% | 8.5 | 404,498 | Common Stock |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 8,498 | 8,498 | - | - | Stock Option (Right to Buy) | |
| Emmett Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 5,408 | 0 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 8,730 | 8,730 | - | - | Stock Option (Right to Buy) | |
| Kevin G. Lokay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 9,888 | 9,888 | - | - | Stock Option (Right to Buy) | |
| Michael F. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 13,179 | 13,179 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 9,888 | 9,888 | - | - | Stock Option (Right to Buy) | |
| Emmett Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 9,888 | 0 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 9,888 | 9,888 | - | - | Stock Option (Right to Buy) | |
| Linda West | Director | Purchase of securities on an exchange or from another person at price $ 9.13 per share. | 15 Jun 2021 | 10,000 | 40,000 (0%) | 0% | 9.1 | 91,300 | Common Stock |
| Lawrence M. Alleva | Director | Purchase of securities on an exchange or from another person at price $ 8.59 per share. | 01 Jun 2021 | 4,045 | 4,045 (0%) | 0% | 8.6 | 34,741 | Common Stock |
| Linda West | Director | Purchase of securities on an exchange or from another person at price $ 8.64 per share. | 28 May 2021 | 10,000 | 20,000 (0%) | 0% | 8.6 | 86,381 | Common Stock |
| Linda West | Director | Purchase of securities on an exchange or from another person at price $ 8.64 per share. | 28 May 2021 | 10,000 | 10,000 (0%) | 0% | 8.6 | 86,410 | Common Stock |
| J. Mel Sorensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.14 per share. | 26 Mar 2021 | 46,940 | 232,044 (0%) | 0% | 1.1 | 53,512 | Common Stock |
| J. Mel Sorensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 46,940 | 0 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 170,075 | 0 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 26 Mar 2021 | 170,075 | 185,104 (0%) | 0% | 1.1 | 181,980 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 71,250 | 71,250 | - | - | Stock Option (Right to Buy) | |
| J. Mel Sorensen | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Arthur J. Fratamico | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Robert A. Beardsley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Joel Sussman | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | Director | Purchase of securities on an exchange or from another person at price $ 10.22 per share. | 13 Nov 2020 | 2,325 | 6,325 (0%) | 0% | 10.2 | 23,771 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 2,639 | 32,238 | - | - | Stock Option (Right to Buy) | |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 3,755 | 0 | - | - | Stock Option (Right to Buy) | |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 3,606 | 0 | - | - | Stock Option (Right to Buy) | |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 10,000 | 3,606 | - | - | Stock Option (Right to Buy) | |
| Joel Sussman | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 12 Nov 2020 | 10,000 | 0 (0%) | 0% | 10.3 | 103,197 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.43 per share. | 12 Nov 2020 | 2,639 | 10,000 (0%) | 0% | 2.4 | 6,413 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.14 per share. | 12 Nov 2020 | 3,755 | 7,361 (0%) | 0% | 1.1 | 4,281 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 12 Nov 2020 | 3,606 | 3,606 (0%) | 0% | 1.1 | 3,858 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Nov 2020 | 10,000 | 0 (0%) | 0% | 10.1 | 100,627 | Common Stock |
| Joel Sussman | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 12 Nov 2020 | 10,000 | 10,000 (0%) | 0% | 1.1 | 10,700 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.43 per share. | 26 Oct 2020 | 2,244 | 2,244 (0%) | 0% | 2.4 | 5,453 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2020 | 2,244 | 108,898 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 26 Oct 2020 | 2,244 | 0 (0%) | 0% | 15 | 33,660 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 05 Oct 2020 | 100 | 100 (0%) | 0% | 1.1 | 107 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 5,632 | 0 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 4,904 | 0 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 05 Oct 2020 | 100 | 0 (0%) | 0% | 12 | 1,200 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 100 | 4,904 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 05 Oct 2020 | 10,536 | 0 (0%) | 0% | 12 | 126,432 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.14 per share. | 05 Oct 2020 | 5,632 | 5,632 (0%) | 0% | 1.1 | 6,420 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 05 Oct 2020 | 4,904 | 4,904 (0%) | 0% | 1.1 | 5,247 | Common Stock |
| Kevin G. Lokay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,888 | 9,888 | - | - | Stock Option (Right to Buy) | |
| Michael F. Powell | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 13,179 | 13,179 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,888 | 9,888 | - | - | Stock Option (Right to Buy) | |
| Emmett Cunningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 9,888 | 0 | - | - | Stock Option (Right to Buy) | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2020 | 692 | 5,004 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 26 May 2020 | 692 | 692 (0%) | 0% | 1.1 | 740 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 26 May 2020 | 692 | 0 (0%) | 0% | 12 | 8,304 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 20 May 2020 | 1,174 | 0 (0%) | 0% | 12 | 14,088 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 20 May 2020 | 1,174 | 1,174 (0%) | 0% | 1.1 | 1,256 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 20 May 2020 | 969 | 0 (0%) | 0% | 12 | 11,628 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 20 May 2020 | 969 | 969 (0%) | 0% | 1.1 | 1,037 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 1,174 | 5,696 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 969 | 6,870 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 08 May 2020 | 185 | 0 (0%) | 0% | 12 | 2,220 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 08 May 2020 | 185 | 185 (0%) | 0% | 1.1 | 198 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 08 May 2020 | 5,102 | 5,102 (0%) | 0% | 1.1 | 5,459 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 08 May 2020 | 5,102 | 0 (0%) | 0% | 12 | 61,224 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2020 | 671 | 7,839 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2020 | 185 | 8,510 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2020 | 5,102 | 8,695 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 08 May 2020 | 671 | 0 (0%) | 0% | 12 | 8,052 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 08 May 2020 | 671 | 671 (0%) | 0% | 1.1 | 718 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 05 May 2020 | 3,064 | 3,064 (0%) | 0% | 1.1 | 3,278 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 2,059 | 13,797 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 1,489 | 15,856 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 3,064 | 17,345 | - | - | Stock Option | |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 05 May 2020 | 2,059 | 0 (0%) | 0% | 12.0 | 24,709 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 05 May 2020 | 2,059 | 2,059 (0%) | 0% | 1.1 | 2,203 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 05 May 2020 | 1,489 | 0 (0%) | 0% | 12 | 17,868 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.07 per share. | 05 May 2020 | 1,489 | 1,489 (0%) | 0% | 1.1 | 1,593 | Common Stock |
| Jon T. Holmlund | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.16 per share. | 05 May 2020 | 3,064 | 0 (0%) | 0% | 12.2 | 37,258 | Common Stock |
| Linda West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 19,776 | 19,776 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Alleva | None | Purchase of securities on an exchange or from another person at price $ 9.78 per share. | 13 Dec 2019 | 4,000 | 4,000 (0%) | 0% | 9.8 | 39,139 | Common Stock |
| Robert A. Beardsley | Chief Operating Officer | 12 Nov 2019 | 15,361 | 68,191 (0%) | 0% | 0 | Common Stock | ||
| Robert A. Beardsley | Chief Operating Officer | 12 Nov 2019 | 68,907 | 0 | - | - | Series A Preferred Stock | ||
| Robert A. Beardsley | Chief Operating Officer | 12 Nov 2019 | 2,000 | 0 | - | - | Series B Preferred Stock | ||
| Robert A. Beardsley | Chief Operating Officer | 12 Nov 2019 | 6,774 | 0 | - | - | Series C Preferred Stock | ||
| Michael F. Powell | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 19,776 | 19,776 | - | - | Stock Option | |
| Emmett Cunningham | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 19,776 | 0 | - | - | Stock Options (Right to Buy) | |
| Christopher Degnan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 229,513 | 229,513 | - | - | Stock Option | |
| Jason Fuller | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 19,776 | 19,776 | - | - | Stock Option |